Market News AIOpen the app

Nasus Pharma has named Nir Sassi as its new Chief Financial Officer starting November 11, 2026.

New bossRead the original at globenewswire.com
Good for NSRX

Nasus Pharma's new CFO brings nearly 25 years in public-company finance and biotech operations, which may help as it prepares NS002's pivotal Phase 3 study. No study results or funding changes were announced, so the benefit is limited to leadership experience.

NSRX · Nasus Pharma Ltd.

AI read · Good for NSRX

The AI's read

That background could help with the planning and finance work around NS002's pivotal study and later product preparations. The announcement gives no study results or funding changes, so the positive reading rests on added experience, not a proven improvement.

Get alerts for NSRX

Follow Nasus Pharma Ltd. (NSRX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for NSRX
Free on the App Store and Google Play, or on the web.